ClinicalTrials.gg
RecruitingNCT05843552Updated Apr 6, 2026

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

An observational study in Gaucher Disease, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by University of Minnesota · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Planned enrollment
28th of 39
30 · median 60
Started
2023
with 2 others
Observational
39 of 92
16 open now
Primary completion
2026-12
later than 6 of 25 live
Registered
82nd of 92
by date
Lead sponsor
6 of 92
University of Minnesota

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 28th largest by planned enrollment of the 39 observational ones that give a count, is one of 3 that started in 2023, is one of 39 observational ones, reaches primary completion later than 6 of the 25 other live ones, and was the 82nd registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

03

Conditions studied

  • Gaucher Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients with GD (n=10 untreated), obligate carriers (n=10) and healthy volunteers (frequency matched for age and gender; n=10) for this study. In the next phase of this project, we will examine the effect of GD treatment on EV characteristics by focusing on patients who are currently being treated and compare various therapies and correlate it with established biomarkers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-80yrs
  • Restricted to participants who are untreated, obligate carriers and healthy controls.
  • Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.

Exclusion criteria

Exclusion Criteria:

  • Exclude participants who have any hematological or other uncontrolled comorbid conditions.
  • Exclude participants who are currently on therapy for their GD
  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • patients with GD

    Other: no intervention

  • obligate carriers

    Other: no intervention

  • healthy volunteers

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention, this is an observational study

06

What researchers measure

Primary outcomes

  1. EVs quantity

    Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: baseline

  2. EVs quantity

    Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: 3months

  3. EVs size

    Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: baseline

  4. EVs size

    Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: 3months

  5. EVs content

    Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: baseline

  6. EVs content

    Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

    Time frame: 3months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
May 6, 2023
StartActual
Aug 14, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05843552
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Aug 14, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Reena Kartha, PhD, MS
Contact
rvkartha@umn.edu
612-626-2436
Marcia Terluk, PhD
Contact
mrterluk@umn.edu
612-625-7972
Reena Kartha, PhD, MS
principal investigator · University of Minnesota
Subbaya Subramanian, PhD, MS
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion